Healthcare Weekly Brief — Week of October 26, 2026

PQT The Setup

PQT Health

Issue live · 2026-10-28

Week of October 26, 2026 · Healthcare Weekly Brief

HCA Absorbs $400M Uninsured Hit; Boston Scientific Cuts Guidance Again

Exchange coverage losses now show up in hospital earnings, Centene raised guidance on a 42% smaller Marketplace book and a cyberattack forced Boston Scientific's third cut of 2026.

Gregory Parker, Ph.D., Christopher Parker / PQT Health, Inc.

HCA $463.52 ▲ bullish IQV $279.01 ▲ bullish CNC $67.03 ◆ mixed BSX $42.44 ▼ bearish UNH $407.25 ◆ mixed LLY $1,289.19 ◆ binary MOH $198.12 ▼ pressured XLV $179.76 93.8% of 52wk range XBI $157.50 80.5% of 52wk range

01

The Setup

The forces shaping this week's market

Q3 earnings put a dollar figure on ACA coverage losses: HCA took a ~$400M pretax hit from uninsured patients yet beat and rose 3.0%, while Centene raised guidance despite a 42% smaller Marketplace book. Boston Scientific cut 2026 guidance a third time and fell 5.8%. XLV closed at $179.76 Oct 28, near its record; XBI rose 3.1% on the week.

01

Uninsured Patients Cost HCA $400M

Q3 adj EPS rose 3.7% to $7.22 on 2.7% admissions growth, but patients who lost exchange coverage cut pretax income ~$400M. Shares rose 3.0% Oct 28.

02

Centene Raises on a Smaller Book

Adj EPS of $0.58 and guidance up $0.40 to above $5.20, even as Marketplace members fell 42% to 3.40M. Shares slipped 2.4%.

03

Boston Scientific's Third Cut

An Aug 25 cyberattack cost ~$150M of Q3 sales; Watchman fell 6% and EP 5%. Q4 sales guided down 1%-3%; shares -5.8% to $42.44.

02

Scorecard

Who wins, who is squeezed

▲ Winner

Scale hospitals and CROs

HCA rose 3.0% Oct 28 after beating with 2.7% admissions growth.
IQVIA raised guidance on 15% bookings growth and rose 2.7%.
XBI gained 3.1% since Oct 21 to $157.50.

$HCA $IQV

▼ Squeezed

Devices and Medicaid plans

Boston Scientific fell 5.8% to a 52-week low after its third guidance cut.
Molina is down 7.9% since Oct 21 to $198.12.
UHS fell 2.9% as Q3 EPS dropped to $5.22 from $5.86.

$BSX $MOH $UHS

◆ Mixed

Payers after the beats

Centene raised guidance yet fell 2.4% Oct 28.
UnitedHealth is down 2.3% since Oct 21 to $407.25.
Elevance is down 4.6% since Oct 21 to $414.35.

$CNC $UNH $ELV

03

The Numbers

Figures that matter this week

HCA Q3 pretax hit from uninsured payer-mix shift

HCA Healthcare 8-K · 2026

~$400M

Centene Marketplace membership, year over year

Centene 8-K · 2026

-42%

Boston Scientific 2026 revenue growth guidance

MedTech Dive · 2026

4.25%

ACA 2027 median proposed premium increase

AARP citing KFF · 2026

15%

10-year Treasury yield, Oct 26

FRED (DGS10) · 2026

5.00%

04

Where Prices Sit

Benchmark levels in their 52-week range

Last available snapshots as of 2026-10-28. The marker shows the current price within the 52-week range.

XLV Health Care Select Sector SPDR

$179.76

$141.97 low 93.8% of range $182.25 high

Up 0.3% Oct 28 and 0.5% since Oct 21; 1.4% below its Oct 22 record high of $182.25. Quoted near $181 after hours.

XBI SPDR S&P Biotech ETF

$157.50

$106.30 low 80.5% of range $169.89 high

Up 1.7% Oct 28 and 3.1% since Oct 21; still 7.3% below its Aug 25 high.

UNH UnitedHealth Group

$407.25

$255.97 low 73.6% of range $461.62 high

Down 0.8% Oct 28 and 2.3% since Oct 21 as payers gave back post-earnings gains.

05

Equity Watch

Names in focus this week

Filter

Sort

Ticker	Company	Sector	Direction	Key Catalyst
`HCA` `$463.52`	HCA Healthcare	Providers	`▲ Bullish, volume-led beat`	Q3 adj EPS $7.22 (+3.7%); same-facility admissions +2.7%; 2026 seen in upper half of guidance Rose 3.0% Oct 28 to $463.52 despite a ~$400M pretax hit from patients who lost exchange coverage. Still 17% below its Mar 12 high of $556.52. `+ WHY IT MATTERS`
`IQV` `$279.01`	IQVIA Holdings	Life Sciences Tools	`▲ Bullish, bookings momentum`	Q3 revenue +8.0% to $4.43B; net new bookings +15%; book-to-bill 1.2x; guidance raised to $12.90-$13.00 Up 2.7% Oct 28 after a 52-week high of $284.50 Oct 27. A $2.1B backlog cleanup of inactive trials is the one item to watch. `+ WHY IT MATTERS`
`CNC` `$67.03`	Centene	Payers/Managed Care	`◆ Mixed, guidance up, stock fading`	Adj EPS $0.58; 2026 guidance raised $0.40 to above $5.20; Marketplace members down 42% Fell 2.4% Oct 28 and sits 7.5% below its Oct 22 high of $72.50. Medicaid HBR of 93.6% shows the core book is not yet repaired. `+ WHY IT MATTERS`
`BSX` `$42.44`	Boston Scientific	MedTech	`▼ Bearish, third guidance cut`	Q4 sales guided -3% to -1%; FY adj EPS cut to $3.16-$3.18; Watchman -6%, EP -5% Fell 5.8% Oct 28 on 69M shares, about 5x normal volume, and hit a 52-week low of $39.57 intraday. Down 60% from its Nov 2025 high of $105.65. `+ WHY IT MATTERS`
`UNH` `$407.25`	UnitedHealth Group	Payers/Managed Care	`◆ Mixed, giving back gains`	Post-Q3 guidance of at least $20.50 adj EPS; ACA open enrollment Nov 1 Down 2.3% since the Oct 21 close of $416.96 and 0.8% Oct 28. Holds 74% of its 52-week range. `+ WHY IT MATTERS`
`LLY` `$1,289.19`	Eli Lilly	Pharma	`◆ Binary catalyst, Q3 Oct 29`	Q3 results Oct 29; obesity franchise growth is the swing factor for XLV Rose 0.6% Oct 28 to $1,289.19 and was quoted near $1,300 after hours. As XLV's largest weight, its print sets the sector's direction this week. `+ WHY IT MATTERS`
`MOH` `$198.12`	Molina Healthcare	Payers/Managed Care	`▼ Pressured, Medicaid repair slow`	Q3 Medicaid MCR of 93.0%; guidance held at $5.25+; Medicaid work requirements begin in January Down 7.9% since the Oct 21 close of $215.15 as the market sided with the 53% EPS drop over the CEO's turnaround call. `+ WHY IT MATTERS`

Prices are point-in-time snapshots; "—" indicates no verified intraday quote. Not a recommendation.

06

One-Week Scenarios

One-week outlook: October 28 - November 4, 2026

Probabilities are analytical judgments. Price ranges are illustrative, not forecasts. Hover a band to isolate its case.

BASE 55%

BULL 20%

BEAR 25%

55%

Base case

Lilly in line, payers drift

Lilly, Merck and Gilead report roughly in line Oct 29, the 10-year holds near 4.95%-5.10% and ACA enrollment opens without surprises. XLV holds near its record, XBI keeps most of its weekly gain and UNH trades sideways into CVS, Cigna and Humana.

XLV $176-$183 XBI $152-$161 UNH $398-$418

20%

Bull case

Lilly beats, rotation extends

Lilly beats and raises on obesity demand, money keeps leaving AI-exposed tech for healthcare and HCA's volume strength lifts hospitals. XLV sets a new record above $182.25 and biotech follows.

XLV $182-$187 XBI $160-$166 UNH $415-$430

25%

Bear case

Pharma disappoints, coverage fears rise

Lilly or Merck guides soft, yields climb above 5.1% and early open-enrollment headlines point to deeper coverage losses. Hospitals and exchange insurers fall together and device names extend losses.

XLV $170-$177 XBI $145-$153 UNH $385-$402

07

The Intelligence Take

What the market is missing

Analyst assessment

The subsidy cliff is now a hospital problem more than an insurer problem; own scale operators like HCA and bookings-driven tools names, and do not buy Boston Scientific on the cyberattack excuse until EP share stabilizes.

01

The subsidy cliff has a clear loser order. Payers repriced and shed members, so Centene can lose 42% of its Marketplace book and still raise guidance. Hospitals cannot shed patients; they absorb the uninsured. HCA has the scale and commercial mix to grow through a $400 million quarterly hit, which is why its stock rose. Smaller and safety-net systems lack that cushion, and UHS's EPS decline on higher volume hints at how margin, not demand, is the pressure point.

02

The payer recovery is real but narrow. Centene's beat came from Medicare, while Medicaid HBR rose to 93.6% and Molina's 93.0% MCR keeps Medicaid books under water into January work requirements. The market is paying for proof, not promises: CNC, UNH and ELV all gave back ground this week even after beats. Expect 2027 Marketplace pricing and enrollment, visible from Nov. 1, to set payer multiples into year-end.

03

Boston Scientific is now a share-loss story, not a cyberattack story. The attack explains $150 million; it does not explain Watchman down 6% or EP down 5% against Medtronic's PFA push. Device investors should separate one-time operational damage from franchise erosion, and treat the Penumbra close slipping to early 2027 as a sign of a stretched balance of priorities. Tools are the cleaner MedTech-adjacent trade, with IQVIA's 15% bookings growth signaling sponsor demand is recovering.

08

Confirmed Facts

What we know with high confidence

✓HCA Q3 adj EPS $7.22 (+3.7%) and revenue $19.85B (+3.6%); uninsured payer-mix shift cut pretax income ~$400M; 2026 seen in upper half of guidance
✓Centene Q3 adj EPS $0.58; 2026 adj EPS guidance raised to above $5.20; Marketplace members 3.40M vs 5.83M; Medicaid HBR 93.6%
✓Boston Scientific cut 2026 adj EPS guidance to $3.16-$3.18 and guided Q4 sales down 1%-3% after an Aug 25 cyberattack cost ~$150M of Q3 revenue
✓IQVIA Q3 revenue +8.0% to $4.43B, book-to-bill 1.2x, 2026 adj EPS guidance $12.90-$13.00
✓FDA approved GSK's Hibsago (bepirovirsen) Oct 20 as the first antisense therapy for chronic hepatitis B, with ~20% functional cure at week 72

09

Risks & Watch

What could break the thesis

!Lilly's Oct 29 Q3 print: as XLV's largest holding, a miss would test the index's position near its $182.25 52-week high
!ACA 2027 open enrollment from Nov 1: early sign-up data will show how many more patients shift to uninsured, the risk HCA and peers now quantify
!Nov 3 elections: ACA subsidy restoration is on the ballot as an issue, and the result moves hospital and exchange-insurer multiples
!Boston Scientific EP share loss to Medtronic's PFA: watch whether Q4 orders recover once cyberattack backlogs clear

10

Key Dates & Catalysts

The calendar ahead

2026-10-29

Eli Lilly, Merck and Gilead Q3; Bristol Myers and Dexcom Q3 (est.)
2026-10-30

FDA action date for INOVIO INO-3107 in recurrent respiratory papillomatosis
2026-11-01

ACA 2027 open enrollment opens in most states
2026-11-03

US elections; Pfizer and Amgen Q3
2026-11-04

CVS Health, Charles River, Zimmer Biomet Q3; Edwards and Penumbra after close
2026-11-06

Humana and Moderna Q3 (Cigna reports Nov 5)

11

Regulatory Landscape

CMS, FDA, and legislative status

FDA

FDA Status

FDA approved GSK and Ionis's Hibsago (bepirovirsen) Oct 20 for chronic hepatitis B in adults on antivirals with HBsAg at or below 3,000 IU/mL, with a Roche companion diagnostic. Daiichi Sankyo and Merck withdrew the I-DXd BLA. INOVIO's INO-3107 has an Oct 30 action date.

CMS

CMS Status

ACA 2027 open enrollment opens Nov 1 in most states, with a median proposed premium increase of 15%, 11 insurers leaving and 6 entering and a moratorium on new brokers. The Transparency in Coverage final rule (Oct 5) moves price files to quarterly and starts a Prescription Drug File schema in November.

LEG

Legislative Status

Enhanced ACA premium tax credits expired at the end of 2025 and have not been restored. Advocates are pressing the issue ahead of the Nov 3 elections; no restoration bill has advanced.

◆

Sources